antibiotic (cefazolin Search Results


95
Chem Impex International cefazolin sodium salt
Cefazolin Sodium Salt, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/Cefazolin+Sodium/boehle_katherine_elizabeth__2018__advancing_point_of_need_bacteria_detection_using_microfluidic_paper_based_analytical_devices-2825-25-28
Average 95 stars, based on 1 article reviews
cefazolin sodium salt - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
Chong Kun Dang antibiotics cefazolin
Antibiotics Cefazolin, supplied by Chong Kun Dang, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotics+cefazolin/pmc07046768-169-3-7
Average 90 stars, based on 1 article reviews
antibiotics cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
West Ward Pharmaceuticals prophylactic antibiotic cefazolin
Prophylactic Antibiotic Cefazolin, supplied by West Ward Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/cefazolin+antibiotic+solution/pmc08320750-65-8-14
Average 90 stars, based on 1 article reviews
prophylactic antibiotic cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sandoz antibiotic (cefazolin
Antibiotic (Cefazolin, supplied by Sandoz, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotics+cefazoline/pm33930307-294-202-213
Average 90 stars, based on 1 article reviews
antibiotic (cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc antibiotic therapy cefazolin 100 mg/kg
Antibiotic Therapy Cefazolin 100 Mg/Kg, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotic+therapy+cefazolin+100+mg+kg/10__3390_slash_coatings11070840-54-0-5
Average 90 stars, based on 1 article reviews
antibiotic therapy cefazolin 100 mg/kg - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Astellas antibiotic cefazolin
Antibiotic Cefazolin, supplied by Astellas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotics+cefazolin/pmc06166051-87-7-18
Average 90 stars, based on 1 article reviews
antibiotic cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Normon Laboratories antibiotic cefazolin cefazolin
Antibiotic Cefazolin Cefazolin, supplied by Normon Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotic+cefazolin+cefazolin/pm40150383-49-6-12
Average 90 stars, based on 1 article reviews
antibiotic cefazolin cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Apothecon Pharmaceuticals antibiotics cefazolin sodium
(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 <t>mg/kg/day</t> for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.
Antibiotics Cefazolin Sodium, supplied by Apothecon Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotics+cefazolin+sodium/pmc02193988-61-28-31
Average 90 stars, based on 1 article reviews
antibiotics cefazolin sodium - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
SoloPak Laboratories cefazolin antibiotic
(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 <t>mg/kg/day</t> for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.
Cefazolin Antibiotic, supplied by SoloPak Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/cefazolin+antibiotic/pmc02953609-33-7-10
Average 90 stars, based on 1 article reviews
cefazolin antibiotic - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Acs Dobfar SPA intravenous antibiotics 1 g cefazolin
(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 <t>mg/kg/day</t> for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.
Intravenous Antibiotics 1 G Cefazolin, supplied by Acs Dobfar SPA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/intravenous+antibiotics+1+g+cefazolin/pm21812906-59-8-12
Average 90 stars, based on 1 article reviews
intravenous antibiotics 1 g cefazolin - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cerner Corporation antibiotic singleshot 1 g cefazoline kefzol
(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 <t>mg/kg/day</t> for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.
Antibiotic Singleshot 1 G Cefazoline Kefzol, supplied by Cerner Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotic+singleshot+1+g+cefazoline+kefzol/pm18763014-60-11-18
Average 90 stars, based on 1 article reviews
antibiotic singleshot 1 g cefazoline kefzol - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pfizer Inc antibiotic cefazolin kefzol
(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 <t>mg/kg/day</t> for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.
Antibiotic Cefazolin Kefzol, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibiotic+(cefazolin/antibiotic+cefazolin+kefzol/pm29728445-40-2-4
Average 90 stars, based on 1 article reviews
antibiotic cefazolin kefzol - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


(a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 mg/kg/day for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.

Journal: The Journal of Experimental Medicine

Article Title: Recipient iNOS but Not eNOS Deficiency Reduces Luminal Narrowing in Tracheal Allografts

doi: 10.1084/jem.20012135

Figure Lengend Snippet: (a) Analysis of tracheal graft sections 3 wk after transplantation. Representative sections (left) and morphometric analysis of sections (right) for each of the indicated conditions. Isografts were WT and allograft recipients were either WT, iNOS −/− , or eNOS −/− . The effect of pharmacologic recipient iNOS inhibition with L-NIL (5 mg/kg/day for 3 wk after transplantation) in WT and eNOS −/− recipients was also examined. Allografts placed in iNOS −/− or iNOS-inhibited recipients demonstrated significantly reduced luminal obliteration compared with WT and eNOS −/− allograft recipients. In contrast, recipient eNOS deficiency was associated with similar degrees of luminal occlusion as WT allograft recipients. *, P < 0.05 versus allografts from WT recipients; #, P < 0.05 versus allografts from iNOS −/− recipients; †, P < 0.05 versus allografts from eNOS −/− recipients. (b) The effect of epithelial versus leukocyte-derived iNOS on graft luminal occlusion. Donor tissue and recipient genotypes were either iNOS +/+ or iNOS −/− , as indicated. Effect of background strain is also indicated here. Genotypes that are underlined represent B10.A strain background. Genotypes that are not underlined represent C57BL/6J. Note that the leftmost three bars represent the same data as is shown in a, repeated here to facilitate comparison. *, P < 0.05.

Article Snippet: All recipient animals received postoperative intramuscular immunosuppression (25 mg/kg/day cyclosporine; Bedford Laboratories) for 2 wk to model acute on chronic airway rejection, and 3 d of antibiotics (20 mg/kg/day cefazolin sodium; Apothecon) to suppress procedure-related infections.

Techniques: Transplantation Assay, Inhibition, Derivative Assay